Biography for Ryan McBride
Ryan McBride is an award-winning journalist who writes about the life sciences industry. Prior to joining FierceMarkets, he was a freelance journalist and served as a correspondent at Xconomy for more than two years. His stories have appeared in The Boston Globe, the Boston Business Journal, The Motley Fool, and many other publications. In recent years, he has also given guest lectures to graduate students at Boston University’s Center for Science & Medical Journalism. Earlier in his career, he held staff reporter positions at Mass High Tech, Providence Business News, and The Westerly Sun. Ryan enjoys spending time with his family and exploring mountains and beaches in New England. Follow Ryan on Twitter at @RyanMFierce or send him e-mail here.
Articles by Ryan McBride
In an effort to advance drug and disease research in children, a unit of the National Institutes of Health aims to fund studies of biomarkers of adult ailments for use in pediatric patients.
Researchers garnered upbeat results from a large clinical trial of a genetic test for organ rejection in patients with transplanted kidneys.
Scientists found a molecular clue in their search for ways to wipe out one of the most devastating tropical diseases on earth. Known as river blindness, Onchocerciasis is a leading cause of vision loss, especially in the developing world. Yet the disease leaves behind a biomarker in the urine of patients that could easily identify those in need of treatment.
Scientists have tied the activity of a life-supporting protein for cells to poor outcomes in patients with the blood cancer multiple myeloma, according to ScienceDaily. And their findings could aid clinicians in diagnosing patients while exposing a target for new therapies.
The U.S. Supreme Court is going to take up a case that could have a major impact on the patentability of genes used in diagnostics.
Seaside Therapeutics wants to home in on which autism patients are likely to respond to its lead drug, STX-209 (arbaclofen). The Cambridge, MA-based biotech won a $2 million award with funds from Autism Speaks, a major research funder and advocate for awareness of autism spectrum disorders (ASDs).